Showing results (941-950 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|August 2, 2024
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effectsLiuyin Jin, Kaixia Yang, Xiping Wu, et al.Expert Opinion on Drug Safety|August 30, 2024
Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosisJames H Lewis, Serena Y Korkmaz, Courtney A Rizk, et al.Expert Opinion on Drug Safety|July 30, 2024
Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillanceFatemeh Zahedi, Anya Jafari, Behnam Nasiri Motlagh, et al.Expert Opinion on Drug Safety|July 29, 2024
Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agentsBurcu Eda Arda, Hande SipahiExpert Opinion on Drug Safety|July 30, 2024
Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS databaseWei Wei, Ying-Tao Bai, En Chang, et al.Expert Opinion on Drug Safety|July 31, 2024
Fluoroquinolones-related psychiatric adverse events: a real‑world retrospective and pharmacovigilance database analysisJuanJuan Li, Xiaohong Yin, Yang Zhao, et al.Expert Opinion on Drug Safety|August 20, 2024
Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargineLockwood G Taylor, Marie-Laure Kürzinger, Ruben Hermans, et al.Expert Opinion on Drug Safety|August 16, 2024
Catatonia related to tacrolimus: a real world pharmacovigilance study of FDA adverse event reporting system (FAERS) databaseJing Yang, Hui Yang, Zhuoling AnExpert Opinion on Drug Safety|August 14, 2024
Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS databaseChun-Yan Xiong, Yong-Min Yang, Ying Zhou, et al.Expert Opinion on Drug Safety|August 14, 2024
Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)Zhicheng Dai, Jiafeng Zhang, Zhengbo Tao, et al.Pageof 282